COMMUNIQUÉS West-GlobeNewswire

CHARM Therapeutics Appoints Dr Erkut Bahceci as Chief Medical Officer
08/09/2025
PRESS RELEASE CHARM Therapeutics Appoints Dr Erkut Bahceci as Chief Medical Officer LONDON – 8 September 2025 -- CHARM Therapeutics (“CHARM”, “The Company”), announces the appointment of Dr Erkut Bahceci as Chief [...]
Novonesis and Novo Nordisk will explore new solutions to improve metabolic health
08/09/2025
Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people. COPENHAGEN, Denmark – September 8, 2025. [...]
ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe
08/09/2025
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The CE Mark certification allows marketing for both clinic and home use First [...]
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
08/09/2025
Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing [...]
Leading Austrian Pathology Laboratory Group Chooses PathAI’s AISight® Dx to Accelerate Digital Pathology and Advanced Diagnostics
08/09/2025
Partnership includes use of PathAI’s CE-IVDR-marked AISight® Dx1 digital pathology image management system at a group of Austrian pathology laboratories BOSTON and VIENNA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PathAI, a [...]
Burning Rock Reports Second Quarter 2025 Financial Results
08/09/2025
GUANGZHOU, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in [...]
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
08/09/2025
BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA (orelabrutinib) has [...]
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
08/09/2025
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]
KFSHRC to Partake Tomorrow as Strategic Partner in C3 Davos of Healthcare™ New York Summit
07/09/2025
NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) will participate tomorrow (Monday) as a Strategic Partner in the C3 Davos of Healthcare™ New York Summit, “ [...]
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
07/09/2025
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Data published in The New England Journal of Medicine demonstrate RYBREVANT®▼(amivantamab) plus LAZCLUZE®▼ (lazertinib) could re-set survival expectations in first-line EGFR-mutated advanced lung cancer
07/09/2025
Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one [...]
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
06/09/2025
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on [...]
Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community
06/09/2025
No-cost access available to qualified researchers via open-source federated data platform SAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit [...]
Lygos Clinic lance des forfaits VIP tout compris pour le tourisme dentaire à destination des patients internationaux
06/09/2025
ISTANBUL, 06 sept. 2025 (GLOBE NEWSWIRE) -- Lygos Clinic, centre dentaire de premier plan à Istanbul, a officiellement lancé ses nouveaux forfaits VIP tout compris de tourisme dentaire , conçus pour répondre à la [...]
CERN’s FPGA Failure and the Suppression of 3D-Flow and 3D-CBS: A Call to Save Millions of Lives and Billions of Euros
06/09/2025
After decades of outreach and evidence—never refuted—it is urgent to fund two 3D-CBS devices that could halve cancer deaths, and to support further press releases to inform taxpayers and decision-makers. No refutations [...]
RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
06/09/2025
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs 1 BEERSE, BELGIUM , Sept. 06, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a [...]
Revive Therapeutics Announces Extension of Proposed Private Placement
06/09/2025
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]

Pages